Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Medulloblastoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39 result(s) found for: Medulloblastoma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-010004-28 Sponsor Protocol Number: ACNS0331 Start Date*: 2010-04-14
    Sponsor Name:COG
    Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas...
    Medical condition: Medulloblastoom standard risk
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027107 Medulloblastoma LLT
    12.0 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002560-10 Sponsor Protocol Number: NOA-07 Start Date*: 2008-11-04
    Sponsor Name:Freistaat Bayern, represented by the University of Regensburg
    Full Title: Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07)
    Medical condition: Therapy of medulloblastoma of adults
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004842-14 Sponsor Protocol Number: CSET2012/1908 Start Date*: 2013-08-16
    Sponsor Name:Institut de cancérologie Gustave Roussy
    Full Title: PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA
    Medical condition: High-risk medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000670-22 Sponsor Protocol Number: 301 Start Date*: Information not available in EudraCT
    Sponsor Name:Y-mAbs Therapeutics, Inc.
    Full Title: A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory M...
    Medical condition: Medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000801-19 Sponsor Protocol Number: MBMET_MEYER2017 Start Date*: 2017-11-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
    Full Title: An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medullobla...
    Medical condition: Metastatic medulloblastoma and other embryonal tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003063-26 Sponsor Protocol Number: 1634 Start Date*: 2023-08-10
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I)
    Medical condition: Newly Diagnosed Medulloblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Trial now transitioned) IT (Prematurely Ended) FR (Prematurely Ended) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003066-40 Sponsor Protocol Number: CLDE225C2301 Start Date*: 2013-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma
    Medical condition: Relapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activation
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) NL (Completed) BE (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004868-30 Sponsor Protocol Number: PNET5MB Start Date*: 2013-10-31
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (...
    Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Trial now transitioned) NL (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004838-37 Sponsor Protocol Number: AloCELYVIR Start Date*: 2021-04-19
    Sponsor Name:Fundación de Investigación Biomédica Hospital Niño Jesús
    Full Title: Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagn...
    Medical condition: Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in children, adolescents and young adults.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080666 Diffuse intrinsic pontine glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001385-38 Sponsor Protocol Number: WIN-HYPO2021 Start Date*: 2021-08-18
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODG...
    Medical condition: medulloblastoma, Hodgkin and non-Hodgkin lymphomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003372-37 Sponsor Protocol Number: ET11-072 Start Date*: 2014-06-04
    Sponsor Name:CENTRE LEON BERARD
    Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre...
    Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004250-17 Sponsor Protocol Number: RG_18-205,BN3010 Start Date*: 2019-10-11
    Sponsor Name:University of Birmingham
    Full Title: An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years
    Medical condition: Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023691-33 Sponsor Protocol Number: MUV-MEMMAT-01 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT
    Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003733-38 Sponsor Protocol Number: ORP-TMZ-I-b Start Date*: 2021-11-27
    Sponsor Name:ORPHELIA Pharma
    Full Title: TEMOkids study (ORP-TMZ-I- b): A Population pharmacokinetic, acceptability and safety study for KIMOZO, a paediatric oral suspension of temozolomide
    Medical condition: Different pediatric cancers such as malignant glioma and also relapsed or refractory neuroblastoma, rhabdomyosarcoma, medulloblastoma, and Ewing sarcoma, for which treatment with the cytotoxic tem...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000095-28 Sponsor Protocol Number: H3E-MC-JMHW Start Date*: 2017-03-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase II Study of Pemetrexed in Children with Recurrent Malignancies
    Medical condition: Recurrent Malignancies (recurrent solid tumors): Target tumor types were osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, neuroblastoma (measurable disease), neuroblastoma (metaiodob...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000570-78 Sponsor Protocol Number: 1520 Start Date*: 2006-07-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR C...
    Medical condition: RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA AND MALIGNANT GLIAL TUMOUR IN CHILDREN AND YOUNG ADULTS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007960 Central nervous system neoplasms malignant NEC HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001512-65 Sponsor Protocol Number: MEMMATCZ Start Date*: 2012-06-19
    Sponsor Name:Masaryk University
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
    Medical condition: recurrent or progressive medulloblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004441-82 Sponsor Protocol Number: CA209-908 Start Date*: 2017-06-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
    Medical condition: Primary central nervous system (CNS) malignancies.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10006153 Brain tumor LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) NO (Completed) NL (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000854-85 Sponsor Protocol Number: CA045-020 Start Date*: 2021-04-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020)
    Medical condition: Recurrent or Refractory pediatric cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-005476-40 Sponsor Protocol Number: A5961166 Start Date*: 2007-02-20
    Sponsor Name:Pfizer Inc
    Full Title: PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA
    Medical condition: children with recurrent or refractory medulloblastoma and newly diagnosed high-grade glioma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061030 Brain tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DK (Completed) IT (Prematurely Ended) PL (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 07:09:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA